Eledon Pharmaceuticals, Inc. ELDN 深 滬
已收盤 08-07 16:00:00 美东时间
3.69
+0.230
+6.65%
華盛通- 最 高3.70
- 今 開3.46
- 成交量 93.01万股
- 最 低 3.44
- 昨 收 3.46
- 總市值 2.85亿
- 52周最高 4.60
- 市盈率 靜 --
- 換手率 1.21%
- 52周最低 1.35
- 委 比 -83.85%
- 總股本 7718.78万
- 歷史最高 154.98
- 量 比 1.04
- 振 幅 7.51%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Zurich-based NewcelX Ltd. announced a private placement of 347,134 common shares at a 20% premium to its July 30 closing price, with warrants exercisable at 132% of that price. The offering, including participation from existing shareholders, is expected to close on Aug. 14. Proceeds will support the advancement of NCEL-101, the company's lead type 1 diabetes program, following a successful FDA Pre-IND meeting. CEO Ronen Twito highlighted investo...
07-31 13:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-21 19:53
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significa...
07-01 21:33
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote
The latest update is out from Eledon Pharmaceuticals ( ($ELDN) ). At its Annual...
06-23 06:47
Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated pat...
06-22 19:15
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW trial for tegoprubart in kidney transplant patients. Results showed sustained kidney function benefits, with a statistically significant 12 mL/min/1.73 m² higher eGFR at 18 months vs. tacrolimus. No biopsy-proven acute rejection (BPAR) events were observed after six months in tegoprubart-treated patients, compared to seven BPAR events in the tacrolimus arm. Patient-report...
06-22 11:00
Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented
06-05 04:33
Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster
05-21 04:16
Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from
05-14 05:32
